BitMart founder Sheldon Xia revealed that threats against employees and alleged retaliation by former staff have made it difficult to retain technical workers, leaving the security team severely understaffed. Despite this, the team continues efforts to protect data and assets. BitMart had previously disclosed a security breach and is now offering users three recovery options, including payouts from liquid assets and tokens linked to future recoveries. The exchange plans to seek court approval for the recovery plan by December or January as it winds down operations by January 2027.
The BitMart founder's staffing challenges provide context for cryptocurrency market conditions. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 06, 2026 05:51 WIB: out of 50 major cryptocurrencies, only 3 rose while 46 fell. Among notable movers, XLM (Stellar) dropped 8.95% to Rp2.789 with a typical hold time of 85 days and a near-even Pluang order activity split. ETH (Ethereum) fell 8.83% to Rp40.433.298, held typically for 108 days, with 82% sell orders. FIL (Filecoin) declined 8.56% to Rp14.520, held for 100 days, with 99% buy orders.
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
Strawberry Fields REIT announced a cash dividend of $0.17 per common share for the fourth quarter of 2026. The dividend will be paid on December 30, 2026, to shareholders recorded by December 16, 2026. The company specializes in owning and leasing he...
Syndax Pharmaceuticals is under investigation by Pomerantz LLP for possible securities fraud following the failure of its MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis, which missed its primary endpoint. The trial news caused ...
Evolus, Inc. is under investigation by Pomerantz LLP following an FDA warning about a misleading Instagram promotion for its wrinkle treatment Jeuveau. The FDA criticized the ad for downplaying safety risks and making exaggerated claims about the pro...
